Thyroid Stimulating but Not Blocking Autoantibodies Are Highly Prevalent in Severe and Active Thyroid-Associated Orbitopathy: A Prospective Study

Table 1

Demographic, clinical, and serological data of the 101 consecutively included patients with severe and active TAO.

GD	= 97
HT	= 4
Female/male	= 76/25
Current smokers	= 53
Median age	52 years (range 23–75)
Median duration of TAO	11 months
Median palpebral aperture	12 mm (6–17 mm)
Median proptosis	22 mm (13–30 mm)
Asymmetric proptosis	= 20
Median CAS	4 (3–6)
Median CSS	5.75 (1–11)
Diplopia	= 63 (12 constant)
Upper lid retraction	= 52
Lower lid retraction	= 42
Chemosis	= 27
Corneal lesions	= 14
TSAb	Median SRR% 418 (28–795)
TBII	Median 7.35 IU/l (0.3–174)

GD: Graves’ disease.
HT: Hashimoto’s thyroiditis.
TAO: thyroid-associated orbitopathy.
CAS: clinical activity score.
CSS: clinical severity score.
TSAb: thyroid stimulating autoantibodies.
TBII: thyroid binding inhibitory immunoglobulins.